| Date |
Subject |
Media |
| 2025-07-06 |
APRINOIA Therapeutics Targets Early Diagnosis Market for Dementia
|
APRINOIA Therapeutics is advancing into the early diagnosis market for dementia. On June 25, company founder Ming-Kuei Jang stated that the presence of Tau protein is highly correlated with neurodegeneration and disease progression, making it a gold standard for early diagnosis. APRINOIA’s lead imaging agent, APN-1607, enables visualization of Tau protein deposition in the brain and is currently undergoing regulatory review in Taiwan, China, the United States, and Japan. Taiwan may become the first market to approve the product. |
| 2025-07-06 |
Sunfun Info Pursues Triple-Growth Strategy in 2025; Subsidiary Daiken Biomedical Gains Listing Approval
|
Sunfun Info held its annual shareholders’ meeting on June 26, chaired by Chairman Chia-Ming Chang, where it approved a fourth-quarter 2024 dividend distribution of NT$0.2036 per share in cash. To strengthen working capital and support future investments in new ventures—particularly in AI and the beauty & housing sectors—the company plans to issue both cash and stock dividends in parallel. Meanwhile, on June 25, its subsidiary Daiken Biomedical received formal approval for its initial public offering from the Taiwan Stock Exchange Board of Directors. |
| 2025-07-06 |
Orient EuroPharma Introduces Cancer-Fighting Photoimmunotherapy in Collaboration with Japan’s Rakuten Medical
|
A new breakthrough in cancer treatment is on the horizon. Orient EuroPharma (OEP) Group has announced that it has secured the commercial rights to Rakuten Medical’s photoimmunotherapy platform in Taiwan, Singapore, Malaysia, and the Philippines. This marks Rakuten Medical’s first licensing agreement with a Taiwanese pharmaceutical company. The therapy is currently undergoing Phase III clinical trials in Taiwan, with the goal of obtaining local regulatory approval next year. Rakuten Medical also plans to consolidate clinical data from Taiwan, the U.S., and Japan to pursue FDA approval in the U.S., further expanding the reach of this innovative treatment. |
| 2025-07-06 |
Sofiva Genomics Advances Precision Medicine with Strategic Focus on Cancer, Dementia, and Reproductive Health
|
At its institutional investor conference on the 25th, Sofiva Genomics outlined its three major strategic priorities, with Chairman Yi-Ning Su personally presenting the company’s vision: integration into Taiwan’s NGS (next-generation sequencing) national health insurance coverage, active expansion into cancer and Alzheimer’s genetic screening markets, and growth in PGT-A applications in assisted reproduction. As the scope of its products and services continues to expand, Sofiva Genomics is poised for a new wave of growth. |
| 2025-07-06 |
EpiSonica Secures Medical Device Approvals in Indonesia and Thailand, Accelerates Southeast Asia Expansion
|
EpiSonica’s flagship product, the ArcBlate MRgHIFU—an image-guided focused ultrasound surgical system—has received market clearance from the Thai Food and Drug Administration, following its approval by Indonesia’s Ministry of Health in late August last year. The device is approved for the treatment of adenomyosis and uterine fibroids. |
| 2025-07-02 |
3D Global Biotech to Launch IPO Application in Q3, Eyes Growth with Pediatric Myopia Control Products
|
3D Global Biotech is set to initiate its IPO process, with plans to submit an application for listing on the Taiwan Innovation Board or over-the-counter (OTC) market as early as the third quarter. Targeting opportunities in the ocular health market, the company leverages its proprietary nano-surface functional crosslinking technology to enhance the water content and moisture retention of contact lenses. Following its initial shipments of adult contact lenses to clients in China at the end of last year, 3D Global Biotech will also introduce orthokeratology lenses for pediatric myopia control, with shipments to China expected in the second half of the year. |
| 2025-07-02 |
Pharmosa Biopharm Announces EU Orphan Drug Designation for Investigational Drug L608
|
Pharmosa Biopharm announced on June 24 that it has received official written notification from the European Commission, confirming that its investigational drug L608 has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of systemic scleroderma (SSc). |
| 2025-07-02 |
Ever Fortune.AI Projects 20–30% Revenue Growth This Year, Teams Up with Phison to Debut AI Healthcare Robot Prototype by Year-End
|
Ever Fortune.AI is targeting the growing burden on frontline healthcare workers by developing an AI-powered medical care robot through its joint venture with Phison Electronics. Their co-founded company, EverBot Technology, is expected to unveil a prototype in the third quarter and make its public debut at a medical technology exhibition by the end of the year. Supported by the ramp-up of its Medical AI product line and continued strong sales of health supplements by its subsidiary, Ever Fortune.AI anticipates a 20–30% year-over-year revenue increase in 2024. |
| 2025-07-02 |
Three Gynecological Drugs to Be Withdrawn: No Benefit in Preventing Preterm Birth and Potential Cancer Risk in Male Offspring
|
Taiwan’s Food and Drug Administration (TFDA) announced that medications containing hydroxyprogesterone caproate will have their licenses revoked by January 2026, following a re-evaluation of their clinical benefits and risks. These drugs are commonly prescribed for gynecological conditions such as dysmenorrhea, irregular menstruation, and recurrent miscarriage. Starting next January, patients and healthcare providers will need to switch to alternative treatments. |
| 2025-07-02 |
New Alzheimer’s Drug May Be Covered by NHI by Year-End? Minister Tai-Yuan Chiu: Subject to HTA Evaluation
|
Far Eastern Memorial Hospital and Easeful Clinic had originally scheduled to administer the new Alzheimer’s drug Kisunla on June 18, but due to flight delays, the medication finally arrived in Taiwan on June 19 and cleared customs smoothly. The first dose in Taiwan is expected to be administered on the morning of June 23. Given that a one-year course of treatment costs over one million NTD, the National Health Insurance Administration (NHIA) plans to discuss by the end of the year whether to include it under coverage. Minister of Health and Welfare Tai-Yuan Chiu stated that the decision will first undergo a formal Health Technology Assessment (HTA) to ensure rational resource allocation. |
